Chronic Kidney Disease
Progressive loss of kidney function due to inflammation, fibrosis, and nephron loss. MSC therapy reduces renal inflammation and supports tubular regeneration.
Chronic kidney disease is characterized by progressive, irreversible loss of glomerular filtration rate and tubular function — driven by sustained inflammation, oxidative stress, and interstitial fibrosis. CKD affects approximately 850 million people globally and is a leading cause of end-stage renal disease requiring dialysis or transplantation.
Common causes include diabetes, hypertension, IgA nephropathy, and polycystic kidney disease. As CKD progresses, declining kidney function leads to fluid retention, electrolyte imbalance, anemia, metabolic acidosis, and accelerated cardiovascular risk. Current treatment focuses on slowing progression through blood pressure control, RAS blockade, and SGLT2 inhibition — but cannot reverse established fibrosis.
MSC therapy is being explored as a strategy to reduce active renal inflammation and support tubular cell repair in CKD patients in earlier stages (G2–G4) where meaningful nephron function remains.
MSCs target the TGF-β-driven fibrotic cascade in the renal interstitium, suppressing myofibroblast activation and collagen deposition. Simultaneously, they reduce mesangial inflammation, downregulate complement pathway activity, and secrete HGF and IGF-1 — which promote tubular epithelial cell survival and proliferation.
Preclinical models of CKD (including diabetic nephropathy and ischemia-reperfusion injury) consistently show that MSC treatment reduces serum creatinine, improves GFR, reduces proteinuria, and decreases interstitial fibrosis on histology. Phase I/II clinical trials have reported stabilization of eGFR decline and reduction in urinary inflammatory markers in treated patients.
True Regen evaluates CKD patients based on current eGFR, creatinine trend, proteinuria, renal ultrasound, and underlying etiology — and tracks kidney function at 3, 6, and 12 months post-treatment.
- Stabilization or improvement of eGFR
- Reduction in proteinuria
- Decreased serum creatinine levels
- Reduced renal inflammatory markers
- Slowed progression toward dialysis
Individual results vary. All patients undergo full medical evaluation prior to treatment.
ISO/cGMP-Certified Lab
Every infusion is manufactured under pharmaceutical-grade controls. You receive a batch-specific Certificate of Analysis before treatment.
High-Dose MSC Protocol
Wharton's jelly umbilical-cord MSCs — younger, more potent, and more consistent than cells from the patient's own body.
Dedicated Coordinator
One person manages every detail of your journey — from your first inquiry through your 12-month follow-up.
Ready to take the next step?
One conversation could change everything.
Your dedicated coordinator will review your case and walk you through the entire process — with zero pressure, zero cost, and zero commitment.